b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">31009169</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>04</Month>\n            <Day>08</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1747-0285</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>94</Volume>\n                    <Issue>2</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>08</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Chemical biology &amp; drug design</Title>\n                <ISOAbbreviation>Chem Biol Drug Des</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Design, synthesis, and biological evaluation of lipophilically modified bisphenol Z derivatives.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1574-1579</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1111/cbdd.13531</ELocationID>\n            <Abstract>\n                <AbstractText>In the present study, a small library of bisphenol Z (BPZ) derivatives was synthesized and investigated for anti-proliferative effects in cultured breast and glioblastoma cell lines. Synthesized BPZ derivatives varied in molecular size, polarity, and lipophilicity. Of the 8 derivatives tested, compounds 4 and 6, both of which displayed the highest degree of lipophilicity, were most active at inducing cell death as determined by the XTT assay. Cell membranes were interrogated using trypan blue staining and were shown to remain intact during treatments with 4 and 6. Activation of caspase enzymes (3 and/or 7) was noted to occur following treatment with compound 4. Polar BPZ derivatives, those with a substituted amine or alcohol, were devoid of any inhibitory or proliferative effects. The remaining derivatives seem to lack sufficient lipophilicity to execute an overt toxic effect. Our results suggest that increasing the lipophilic character of BPZ enhances the cytotoxic effects.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2019 John Wiley &amp; Sons A/S.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Stitzlein</LastName>\n                    <ForeName>Lea M</ForeName>\n                    <Initials>LM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>College of Pharmacy, The University of Findlay, Findlay, Ohio.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Stang</LastName>\n                    <ForeName>Christopher R T</ForeName>\n                    <Initials>CRT</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>College of Pharmacy, The University of Findlay, Findlay, Ohio.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Inbody</LastName>\n                    <ForeName>Laura R</ForeName>\n                    <Initials>LR</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>College of Pharmacy, The University of Findlay, Findlay, Ohio.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rao</LastName>\n                    <ForeName>P S S</ForeName>\n                    <Initials>PSS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>College of Pharmacy, The University of Findlay, Findlay, Ohio.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Schneider</LastName>\n                    <ForeName>Ryan A</ForeName>\n                    <Initials>RA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>College of Pharmacy, The University of Findlay, Findlay, Ohio.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Dudley</LastName>\n                    <ForeName>Richard W</ForeName>\n                    <Initials>RW</Initials>\n                    <Identifier Source="ORCID">0000-0001-5020-371X</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>College of Pharmacy, The University of Findlay, Findlay, Ohio.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016422">Letter</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>05</Month>\n                <Day>16</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Chem Biol Drug Des</MedlineTA>\n            <NlmUniqueID>101262549</NlmUniqueID>\n            <ISSNLinking>1747-0277</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">\nXTT\n</Keyword>\n            <Keyword MajorTopicYN="Y">apoptosis</Keyword>\n            <Keyword MajorTopicYN="Y">bisphenol Z</Keyword>\n            <Keyword MajorTopicYN="Y">cytotoxicity</Keyword>\n            <Keyword MajorTopicYN="Y">derivative synthesis</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>12</Month>\n                <Day>11</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>12</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>31</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>23</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31009169</ArticleId>\n            <ArticleId IdType="doi">10.1111/cbdd.13531</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'